Big Money Positive on Alkermes Inc (NASDAQ:ALKS), Sentiment at 1.17

“Big money” Positions

In 2018 Q3 Alkermes Inc (NASDAQ:ALKS) big money sentiment increased to 1.17, revealed SEC filings. That’s up 0.35, from 2018Q2’s 0.82. 97 hedge funds increased and opened new equity positions, while 83 sold and reduced holdings in Alkermes Inc so the sentiment improved. Funds own 152.54 million shares, up from 152.15 million shares in 2018Q2. Funds holding Alkermes Inc in top 10 was flat from 1 to 1 for the same number . In total 22 funds closed positions, 61 reduced and 57 increased. Also 40 funds bought new Alkermes Inc stakes.

Most Alkermes Inc Shareholders

As of 2018 Q3 Meditor Group Ltd has 9.4% invested in Alkermes Inc. As of 2018 Q3, 25,242 shares of Alkermes Inc are owned by Opus Point Partners Management Llc. Rhenman & Partners Asset Management Ab reported 301,610 shares. Roanoke Asset Management Corp Ny revealed 57,386 shares position in Alkermes Inc. The Massachusetts-based fund Twin Focus Capital Partners Llc holds 32,500 shares or 0.71% of their fund portfolio.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products that are designed to address unmet medical needs of patients in various therapeutic areas worldwide.The firm is valued at $5.36 billion. The companyÂ’s marketed products include ARISTADA for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) for the treatment of type 2 diabetes.Last it reported negative earnings. It is also developing ALKS 5461 that is in Phase III clinical trials for the treatment of depressive disorder; ALKS 3831, which is in Phase III clinical trials to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is in Phase III clinical trials to treat multiple sclerosis; ALKS 6428, which is in Phase III clinical trials to help physicians transition patients from physical dependence on opioids; and Aripiprazole lauroxil, an injectable atypical antipsychotic, which has completed a Phase I clinical trials for the treatment of schizophrenia, as well as ALKS 4230, a cell activator that is in Phase I clinical trials for cancer immunotherapy.

Ticker’s shares touched $34.47 during the last trading session after 0.55% change.Alkermes plc has volume of 767,285 shares. Since December 12, 2017 ALKS has declined 35.03% and is downtrending. ALKS underperformed by 35.03% the S&P 500.

On February, 13. Investors wait Alkermes plc (NASDAQ:ALKS) to report its quarterly earnings, Zacks reports. Analysts forecast 250.00 % diference or $-0.30 from the $0.2 EPS from 2017. Wall Street now sees 275.00 % negative EPS growth despite Alkermes plc previous quarter’s EPS of $-0.08.

Eaton Vance Mngmt invested 0% in Alkermes plc (NASDAQ:ALKS). Robeco Institutional Asset Mgmt Bv reported 0% in Alkermes plc (NASDAQ:ALKS). Nelson Van Denburg Campbell Wealth Mngmt Grp Llc holds 0.02% or 2,016 shs. Art Advsr Limited Liability Company stated it has 0.03% in Alkermes plc (NASDAQ:ALKS). D E Shaw & Inc has invested 0.01% in Alkermes plc (NASDAQ:ALKS). Vanguard has 0.02% invested in Alkermes plc (NASDAQ:ALKS) for 13.22M shs. Blackrock stated it has 0.02% of its capital in Alkermes plc (NASDAQ:ALKS). Wells Fargo Co Mn holds 0% in Alkermes plc (NASDAQ:ALKS) or 342,481 shs. Virtu Financial Ltd Liability Corporation reported 0% stake. Opus Point Mngmt Lc, a New York-based fund reported 25,242 shs. New York-based Quantbot L P has invested 0.03% in Alkermes plc (NASDAQ:ALKS). Amundi Pioneer Asset accumulated 0% or 53,121 shs. Franklin Res holds 0.09% in Alkermes plc (NASDAQ:ALKS) or 4.27M shs. Comerica Bancshares invested in 0% or 9,203 shs. Sei Investments holds 0.02% or 128,509 shs in its capital.

Alkermes plc (NASDAQ:ALKS) Ratings Coverage

A total of 7 analysts rate Alkermes (NASDAQ:ALKS) as follows: 2 “Buy”, 4 “Hold” and 1 “Sell”. Тherefore 29% are bullish. The firm has $54 highest and $36 lowest target. The avg target $44.14 is 28.05% above the last ($34.47) price. (NASDAQ:ALKS) has 8 ratings reports on 12 Dec 2018 according to StockzIntelligence. On Friday, July 27 the rating was maintained by Bank of America with “Buy”. The company rating was maintained by Credit Suisse on Friday, July 27. In Tuesday, November 6 report Cantor Fitzgerald maintained the stock with “Neutral” rating. The stock rating was downgraded by Morgan Stanley to “Underweight” on Thursday, June 21.

For more Alkermes plc (NASDAQ:ALKS) news posted recently go to:,,, or The titles are as follows: “Health Care Sector Update for 11/29/2018: ONCY,EYPT,ALKS – Nasdaq” posted on November 29, 2018, “ETF Preview: ETFs, Futures Lower Ahead of FOMC Meeting Minutes, US-China Trade Talks – Nasdaq” on November 29, 2018, “Alkermes up 3% on accelerated plan for ALKS 4230 – Seeking Alpha” with a publish date: November 06, 2018, “Why Alkermes Tumbled 15% Today – Motley Fool” and the last “Health Care Sector Update for 11/29/2018: ALKS,EYPT,JAZZ – Nasdaq” with publication date: November 29, 2018.

Alkermes plc (NASDAQ:ALKS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.